NCT00520390已完成1 期
A Phase I, Multicenter, Open-Label, Dose-Escalation Study Evaluating the Safety and Tolerability of Intravenous EZN-2208 PEG-SN38) Administered Weekly for 3 Weeks in 4-Week Cycles in Patients With Advanced Solid Tumors or Ymphoma (EZN-2208-02)
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 34
- 试验地点
- 2
- 主要终点
- Determine the MTD of i.v. EZN-2208 administered weekly for 3 weeks in a 4-week cycle and recommended Phase 2 dose of i.v. EZN-2208
研究概览
简要总结
The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to patients with advanced cancer or lymphoma. The safety of the study drug and its effect on the disease will also be studied.
Enzon will also perform pharmacokinetic (PK) testing of EZN-2208. PK testing measures the amount of a drug in the body at different time points.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically or cytologically confirmed diagnosis of advanced and/or metastatic solid tumor or lymphoma that is refractory to standard therapy
- •Measurable or evaluable disease
- •Score of 0 to 2 on the ECOG performance scale
排除标准
- •Concurrent serious medical illness
- •Known, clinically suspected, or history of central nervous system (CNS) tumor involvement
- •Active diarrhea
- •Known history of coagulation disorder
- •Patients requiring cytochrome P450 3A4 (CYP3A4) enzyme inducing medications
- •Requirement for ketoconazole or other strong inhibitor of CYP3A4 enzymes
- •Prior chemotherapy, immunotherapy, investigational agent, or other therapy used to treat the cancer within 4 weeks (6 weeks for prior treatment with mitomycin C or nitrosoureas) prior to the scheduled administration of EZN-2208.
结局指标
主要结局
Determine the MTD of i.v. EZN-2208 administered weekly for 3 weeks in a 4-week cycle and recommended Phase 2 dose of i.v. EZN-2208
次要结局
- Evaluate the safety and tolerability of EZN-2208, assess the pharmacokinetic PK profile of EZN-2208, SN38, and SN38G.(1.5 years)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Phase I, Study to Evaluate the Safety and Tolerability of Intravenous EZN-2208 in Patients With Advanced Solid Tumors or Lymphoma (EZN-2208-01)Advanced Solid TumorsLymphomaNCT00520637Enzon Pharmaceuticals, Inc.34
终止
1 期
Study of EZN-2208 Pediatric Patients With Solid TumorsSolid TumorsNCT01295697Enzon Pharmaceuticals, Inc.32
撤回
1 期
A Study of Safety, Tolerability, and Pk of rhMBL in Pediatric Hematology/Oncology Pts With Fever and NeutropeniaHematologic DiseasesFeverNeutropeniaCancerNCT00520325Enzon Pharmaceuticals, Inc.
已完成
1 期
Safety Study of an Immunomodulating Microparticle to Treat Progressive Multiple SclerosisPrimary Progressive Multiple SclerosisSecondary Progressive Multiple SclerosisNCT01191996Innate Immunotherapeutics34
终止
1 期
PF-07284892 in Participants With Advanced Solid TumorsSolid TumorNCT04800822Pfizer53